AstraZeneca looks to China for kidney disease R&D

AstraZeneca ($AZN) has struck up a partnership with the Shenzhen University Health Science Center to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China's aging population. Under the deal, the two will focus on diabetic nephropathy, and AstraZeneca said the partnership is part of its efforts to stand up a product-generating operation in the country. More